Sangamo Therapeutics Inc. (SGMO)
Sangamo Therapeutics Statistics
Share Statistics
Sangamo Therapeutics has 224.71M shares outstanding. The number of shares has increased by 2.44% in one year.
| Shares Outstanding | 224.71M |
| Shares Change (YoY) | 2.44% |
| Shares Change (QoQ) | 0.2% |
| Owned by Institutions (%) | 29.52% |
| Shares Floating | 214.59M |
| Failed to Deliver (FTD) Shares | 141 |
| FTD / Avg. Volume | < 0.01% |
Short Selling Information
The latest short interest is 22.45M, so 10.76% of the outstanding shares have been sold short.
| Short Interest | 22.45M |
| Short % of Shares Out | 10.76% |
| Short % of Float | 11.27% |
| Short Ratio (days to cover) | 1.97 |
Valuation Ratios
The PE ratio is -2.1 and the forward PE ratio is -5.19. Sangamo Therapeutics's PEG ratio is 0.03.
| PE Ratio | -2.1 |
| Forward PE | -5.19 |
| PS Ratio | 3.56 |
| Forward PS | 0.6 |
| PB Ratio | 9.04 |
| P/FCF Ratio | -3.05 |
| PEG Ratio | 0.03 |
Enterprise Valuation
Sangamo Therapeutics Inc. has an Enterprise Value (EV) of 132.88M.
| EV / Earnings | -1.36 |
| EV / Sales | 2.3 |
| EV / EBITDA | -1.49 |
| EV / EBIT | -1.28 |
| EV / FCF | -1.97 |
Financial Position
The company has a current ratio of 1.13, with a Debt / Equity ratio of 1.34.
| Current Ratio | 1.13 |
| Quick Ratio | 1.13 |
| Debt / Equity | 1.34 |
| Total Debt / Capitalization | 57.31 |
| Cash Flow / Debt | -2.2 |
| Interest Coverage | 0 |
Financial Efficiency
Return on equity (ROE) is -4.3% and return on capital (ROIC) is -194.6%.
| Return on Equity (ROE) | -4.3% |
| Return on Assets (ROA) | -0.96% |
| Return on Capital (ROIC) | -194.6% |
| Revenue Per Employee | $315,846.99 |
| Profits Per Employee | $-535,196.72 |
| Employee Count | 183 |
| Asset Turnover | 0.57 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | -167K |
| Effective Tax Rate | 0 |
Stock Price Statistics
The stock price has increased by 22.35% in the last 52 weeks. The beta is 1.5, so Sangamo Therapeutics's price volatility has been higher than the market average.
| Beta | 1.5 |
| 52-Week Price Change | 22.35% |
| 50-Day Moving Average | 1.04 |
| 200-Day Moving Average | 1.16 |
| Relative Strength Index (RSI) | 37.44 |
| Average Volume (20 Days) | 5.97M |
Income Statement
In the last 12 months, Sangamo Therapeutics had revenue of 57.8M and earned -97.94M in profits. Earnings per share was -0.49.
| Revenue | 57.8M |
| Gross Profit | 57.8M |
| Operating Income | -103.97M |
| Net Income | -97.94M |
| EBITDA | -89.09M |
| EBIT | -103.97M |
| Earnings Per Share (EPS) | -0.49 |
Balance Sheet
The company has 41.92M in cash and 30.57M in debt, giving a net cash position of 11.35M.
| Cash & Cash Equivalents | 41.92M |
| Total Debt | 30.57M |
| Net Cash | 11.35M |
| Retained Earnings | -1.5B |
| Total Assets | 101.64M |
| Working Capital | 5.89M |
Cash Flow
In the last 12 months, operating cash flow was -67.14M and capital expenditures -267K, giving a free cash flow of -67.41M.
| Operating Cash Flow | -67.14M |
| Capital Expenditures | -267K |
| Free Cash Flow | -67.41M |
| FCF Per Share | -0.33 |
Margins
Gross margin is 100%, with operating and profit margins of -179.88% and -169.45%.
| Gross Margin | 100% |
| Operating Margin | -179.88% |
| Pretax Margin | -169.74% |
| Profit Margin | -169.45% |
| EBITDA Margin | -154.13% |
| EBIT Margin | -179.88% |
| FCF Margin | -116.62% |
Dividends & Yields
SGMO does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -59.76% |
| FCF Yield | -36.48% |
Analyst Forecast
The average price target for SGMO is $4, which is 387.8% higher than the current price. The consensus rating is "Buy".
| Price Target | $4 |
| Price Target Difference | 387.8% |
| Analyst Consensus | Buy |
| Analyst Count | 6 |
Scores
| Altman Z-Score | -21.83 |
| Piotroski F-Score | 3 |